A Study of Anaprazole Sodium Enteric-coated Tablets in the Treatment of Reflux Esophagitis
Status:
Not yet recruiting
Trial end date:
2024-03-01
Target enrollment:
Participant gender:
Summary
A phase 2, randomized, double-blind, double-dummy, positive drug parallel controlled,
multicenter trial to evaluate efficacy and safety of within 8 weeks (including 8 weeks)
treatment of Anaprazole 40mg QD, 60mg QD compared with Rabeprazole 20mg QD in patients with
reflux esophagitis.